By Ben Hirschler LONDON (Reuters) – AstraZeneca has seen off a remaining threat to its top-selling cholesterol drug Crestor by settling a U.S. legal case with generic firms Watson Laboratories, a unit of Actavis , and Egis . The settlement follows a U.S. appeal court ruling in December involving other firms upholding the patent on the medicine, which AstraZeneca is relying on as sales of other products tumble. AstraZeneca said on Monday that Watson and Egis had both conceded the Crestor substance patent was valid under the latest deal. …
There are no comments yet. Why not be the first to speak your mind.